August 30, 2023
Today, PILMA released the following statement in response to the Centers for Medicare & Medicaid Services (CMS) announcement on the first list of medicines in Medicare to be subject to price controls:
Today’s announcement by CMS is government price controls on medicines in Medicare under the guise of negotiation. PILMA has long opposed price controls in any form due to their deleterious impacts on future innovation, patient access to treatments and cures, capital construction and manufacturing investment, and U.S. jobs.
Decreased innovation and investment will directly impact U.S. manufacturing, construction, and science technology jobs and training and will threaten U.S. standing as the global leader in new medicine and development.
PILMA will continue to advocate for policies that foster innovation and support ongoing building and construction jobs here in the U.S. Any legislative solutions that aim to lower the cost of medicines for patients must reform the entire supply chain, including the unfair business practices by PBMs and insurers.